



**HAL**  
open science

## Inhaled colistin for the treatment of tracheobronchitis and pneumonia in critically ill children without cystic fibrosis

Matthew E Falagas, Georgia Sideri, Ioanna P. Korbila, Evridiki Vouloumanou, John H. Papadatos, Dimitris A. Kafetzis

► **To cite this version:**

Matthew E Falagas, Georgia Sideri, Ioanna P. Korbila, Evridiki Vouloumanou, John H. Papadatos, et al.. Inhaled colistin for the treatment of tracheobronchitis and pneumonia in critically ill children without cystic fibrosis. *Pediatric Pulmonology*, 2010, 45 (11), pp.1135. 10.1002/ppul.21302 . hal-00588666

**HAL Id: hal-00588666**

**<https://hal.science/hal-00588666>**

Submitted on 26 Apr 2011

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



**Inhaled colistin for the treatment of tracheobronchitis and pneumonia in critically ill children without cystic fibrosis**

Journal:	<i>Pediatric Pulmonology</i>
Manuscript ID:	PPUL-10-0037.R1
Wiley - Manuscript type:	Original Article
Date Submitted by the Author:	19-Mar-2010
Complete List of Authors:	Falagas, Matthew; Alfa Institute of Biomedical Sciences (AIBS), Department of Medicine Sideri, Georgia; Pediatric Intensive Care Unit, P. & A. Kyriakou Children's Hospital, Athens, Greece Korbila, Ioanna; Alfa Institute of Biomedical Sciences (AIBS), Athens, Greece Vouloumanou, Evridiki; Alfa Institute of Biomedical Sciences (AIBS), Athens, Greece Papadatos, John; Pediatric Intensive Care Unit, P. & A. Kyriakou Children's Hospital, Athens, Greece Kafetzis, Dimitris; Second Department of Pediatrics, University of Athens, P. & A. Kyriakou Children's Hospital, Athens, Greece
Keywords:	Gram-negative infections, polymyxins, Pseudomonas, Acinetobacter, intensive care unit



1  
2  
3  
4 **1 Inhaled colistin for the treatment of tracheobronchitis and pneumonia**  
5  
6 **2 in critically ill children without cystic fibrosis**  
7  
8  
9

10 Matthew E. Falagas<sup>1,2,3</sup>, MD, MSc, DSc, Georgia Sideri<sup>4</sup>, MD, Ioanna P. Korbila<sup>1</sup>, MD,  
11 Evridiki K. Vouloumanou<sup>1</sup>, MD, John H. Papadatos<sup>4</sup>, MD, PhD,  
12 Dimitris A. Kafetzis<sup>5</sup>, MD, PhD  
13  
14  
15  
16

17 1. Alfa Institute of Biomedical Sciences (AIBS), Athens, Greece

18 2. Department of Medicine, Henry Dunant Hospital, Athens, Greece

19 3. Department of Medicine, Tufts University School of Medicine, Boston,  
20 Massachusetts, USA

21 4. Pediatric Intensive Care Unit, P. & A. Kyriakou Children's Hospital, Athens, Greece

22 5. Second Department of Pediatrics, University of Athens, P. & A. Kyriakou Children's  
23 Hospital, Athens, Greece  
24  
25  
26  
27  
28  
29  
30  
31

32 **Corresponding author:** Matthew E. Falagas, MD, MSc, DSc

33 Alfa Institute of Biomedical Sciences (AIBS),

34 9 Neapoleos Street, 151 23 Marousi, Greece

35 Tel: +30 (694) 611-0000,

36 Fax: +30 (210) 683-9605

37 E-mail: m.falagas@aibs.gr  
38  
39  
40  
41  
42  
43

44 **Short title:** Inhaled colistin in children without cystic fibrosis.

45 **Conflict of interest:** None

46 **Funding:** None

47 **Word counts:** abstract: 199, text: 1857

48 **Number of tables:** 1

49 **Number of references:** 26  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

29 **Abstract**

30 Data regarding the role of inhaled colistin in critically ill pediatric patients without  
31 cystic fibrosis are scarce. Three children (1 female), admitted to the intensive care unit  
32 (ICU) of a tertiary-care pediatric hospital in Athens, Greece, during 2004-2009 received  
33 inhaled colistin as monotherapy for tracheobronchitis (2 children), and as adjunctive  
34 therapy for necrotizing pneumonia (1 child). Colistin susceptible *Acinetobacter*  
35 *baumannii* and *Pseudomonas aeruginosa* were isolated from the cases' bronchial  
36 secretions specimens. All 3 children received inhaled colistin in a dosage of 75mg  
37 diluted in 3ml of normal saline twice daily (1.875.000 IU of colistin daily), for a  
38 duration of 25, 32, and 15 days respectively. The infections improved in all 3 cases.  
39 Also, a gradual reduction, and finally total elimination of the microbial load in bronchial  
40 secretions was observed during inhaled colistin treatment in the reported cases. All 3  
41 cases were discharged from the ICU. No bronchoconstriction or any other type of  
42 toxicity of colistin was observed. In conclusion, inhaled colistin was effective and safe  
43 for the treatment of 2 children with tracheobronchitis, and 1 child with necrotizing  
44 pneumonia. Further studies are needed to clarify further the role of inhaled colistin in  
45 pediatric critically ill patients without cystic fibrosis.

46  
47 **Keywords:** Gram-negative infections, polymyxins, *Pseudomonas*, *Acinetobacter*,  
48 intensive care unit

## 49 Introduction

50 The use of inhaled antibiotics for the prevention and treatment of **difficult-to-treat**  
51 infections of the respiratory tract has been investigated over the past years. Inhaled  
52 tobramycin and colistin are recommended as an early eradication and maintenance  
53 therapy in patients with cystic fibrosis and chronic *Pseudomonas aeruginosa* infection.<sup>1-</sup>  
54 <sup>3</sup> Inhaled pentamidine is suggested as an alternative prophylactic regimen against  
55 *Pneumocystis jirovecii* pneumonia in immunocompromised patients.<sup>4</sup> Inhaled ribavirin  
56 is also used to treat severe infections of the lower respiratory tract in children caused by  
57 respiratory syncytial virus (RSV).<sup>5</sup> Inhaled zanamivir is proven effective for the  
58 treatment of influenza infection and the prevention of influenza outbreaks.<sup>6,7</sup>

59  
60 The strategy of antimicrobial drug delivery through inhalation has been tested in adult  
61 and children population. Specifically, regarding colistin, several studies in adult and  
62 pediatric patients with cystic fibrosis have investigated the role of inhaled colistin to  
63 eradicate *Pseudomonas aeruginosa*, which chronically colonizes the respiratory tract, as  
64 well as its adverse events.<sup>8-11</sup> **Patients on mechanical ventilation constitute a high-risk**  
65 **group for difficult-to-treat respiratory infections, including both ventilator -associated**  
66 **tracheobronchitis (VAT) and ventilator-associated pneumonia (VAP).**<sup>12,13</sup> Recent data  
67 provide preliminary evidence of inhaled colistin's value to cure difficult-to-treat  
68 infections of the respiratory tract caused by multi-drug resistant Gram-negative  
69 pathogens such as *Pseudomonas aeruginosa*, *Acinetobacter baumannii*, and *Klebsiella*  
70 *pneumoniae* in the intensive care unit (ICU) setting in patients without cystic fibrosis.<sup>14-</sup>  
71 <sup>18</sup> On the other hand, in the field of pediatric critical care medicine there is a lack of  
72 evidence regarding the role of inhaled colistin to treat such infections.<sup>19,20</sup>

73  
74 In this regard, in this small case series **we present** data regarding critically ill pediatric  
75 patients hospitalized in the ICU of a tertiary care pediatric hospital in Athens, Greece,  
76 who did not suffer from cystic fibrosis and received inhaled colistin for infections of the  
77 lower respiratory tract.

## 79 Case description

1  
2  
3  
4  
5 80 Children who received inhaled colistin (colistimethate sodium) [1mg equals 12.500  
6 81 international units (IU) of colistin base activity] in the ICU of the A. & P. Kyriakou  
7 82 tertiary-care pediatric hospital during 2004-2009, were identified by reviewing ICU  
8 83 records. Data presented in this study were extracted from medical charts. Specifically,  
9 84 data regarding the demographical characteristics, underlying disease, reason for ICU  
10 85 admission, length of stay in the ICU and duration of ventilation, type of infection, site  
11 86 of isolation, and susceptibility pattern of each isolated pathogen, whether intravenous  
12 87 colistin was administered prior to inhaled colistin, the device used to deliver inhaled  
13 88 colistin, the type of the ventilator used, and presence of humidification, as well as time  
14 89 of institution, dosage and duration of inhaled colistin treatment, any concomitantly  
15 90 administered antibiotics, quantitative measures of the microbial load, the outcome and  
16 91 any adverse event reported are presented in the Table. The collection and report of the  
17 92 data presented in our study was approved from the hospital's ethical committee.  
18 93 Specifically, this report on inhaled colistin constitutes a nested study within a larger one  
19 94 regarding the toxicity of rarely administered (either intravenously or through inhalation)  
20 95 antimicrobial agents in children.  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33

### 34 97 **Case 1**

35 98 Case 1 was a 10-year-old male suffering from acute disseminated encephalomyelitis  
36 99 attributed to infection with influenza B virus. This child stayed in the ICU for 7 months  
37 100 and developed 5 episodes of septicemia and 2 episodes of septic shock for which he  
38 101 received various antibiotics. Polymyxin-only-susceptible *Acinetobacter baumannii* was  
39 102 isolated in one blood culture, and the infection was cured with the administration of  
40 103 intravenous colistin. The child had a clinical picture of tracheobronchitis, with a high  
41 104 microbial load of *Acinetobacter baumannii* and *Pseudomonas aeruginosa* in cultures of  
42 105 tracheobronchial secretions (the susceptibility pattern of these isolates is presented in  
43 106 the Table). In this regard, inhaled colistin was administered alone at a dosage of 75mg  
44 107 diluted in 3 ml of normal saline twice daily (this equals to a daily dosage of 1.875.000  
45 108 IU of colistin, administered in 2 divided doses) for 25 days. At day 21 of inhaled  
46 109 colistin treatment, a culture of tracheobronchial secretions with normal flora was  
47 110 obtained. Bronchoconstriction, attributed to the tracheobronchitis, was present before  
48 111 the initiation of inhaled colistin and was unsuccessfully treated with bronchodilators  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4  
5 112 (specifically, salbutamol, ipratropium). Bronchoconstriction did not worsen during  
6 113 treatment. The outcome of the infection was favorable. However, the child exhibited  
7 114 serious neurological deficiencies that led to the need of permanent tracheostomy and  
8 115 gastrostomy.  
9  
10  
11  
12

### 13 Case 2

14  
15 118 Case 2 was a 7.5-month-old female with no underlying disease, nor immuno-  
16 119 deficiencies who was admitted at the ICU with septic shock due to necrotizing  
17 120 pneumonia caused by *Pseudomonas aeruginosa*, which was isolated in blood and  
18 121 bronchial secretions cultures obtained at the day of admission in the ICU. The  
19 122 susceptibility pattern of the *Pseudomonas aeruginosa* is presented at the Table. The  
20 123 child received various intravenous antibiotic agents. Inhaled colistin was initiated 3  
21 124 days after the acquisition of the index cultures at a dosage of 75 mg diluted in 3 ml of  
22 125 normal saline twice daily (a daily dosage of 1.875.000 IU of colistin), administered in 2  
23 126 divided doses) for 32 days. Concomitant to inhaled colistin administration of  
24 127 intravenous antibiotic regimens included piperacillin/tazobactam and gentamicin for the  
25 128 first 10 days of administration of colistin and meropenem plus vancomycin (due to the  
26 129 isolation of *Staphylococcus coagulase-negative* from blood culture) for the following 11  
27 130 days. During the course of the infection the child developed bilateral pleural effusions.  
28 131 Culture of the pleural fluid led to *Pseudomonas aeruginosa* isolation, as well. At day 32  
29 132 after the institution of inhaled colistin a culture consisting of normal flora was obtained.  
30 133 Bronchoconstriction was not observed at anytime during treatment. The infection was  
31 134 cured and the child was extubated and discharged from the ICU.  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46

### 47 Case 3

48  
49 137 Case 3 was a 4-year-old female with no underlying disease who was admitted in the  
50 138 ICU with acute respiratory distress syndrome due to thermal burn of the airway  
51 139 requiring tracheostomy. The child received a variety of intravenous antibiotics before  
52 140 the administration of inhaled colistin because of 3 episodes of septicemia due to  
53 141 *Pseudomonas aeruginosa*, *Escherichia coli* and *Staphylococcus coagulase negative*.  
54 142 *Pseudomonas aeruginosa* septicemia was treated successfully with intravenous colistin.  
55 143 *Pseudomonas aeruginosa* was also isolated from cultures of tracheobronchial  
56  
57  
58  
59  
60

1  
2  
3  
4  
5 144 secretions. The susceptibility pattern of this isolate is presented in the Table. However,  
6  
7 145 due to the observed clinical picture of tracheobronchitis and the persistence of a high  
8  
9 146 microbial load of *Pseudomonas aeruginosa* in tracheobronchial secretions (>100.000  
10  
11 147 cfu/ml), inhaled colistin alone was administered at a dosage of 75 mg diluted in 3 ml of  
12  
13 148 normal saline twice daily for 15 days (a daily dosage of 1.875.000 IU of colistin,  
14  
15 149 administered in 2 divided doses). At day 11 of the administration of inhaled colistin a  
16  
17 150 culture of tracheobronchial secretions consisting of normal flora was obtained.  
18  
19 151 Bronchoconstriction, attributed to the tracheobronchitis, was present before the  
20  
21 152 initiation of inhaled colistin and was unsuccessfully treated with bronchodilators  
22  
23 153 (specifically, salbutamol, ipratropium). Bronchoconstriction did not worsen during  
24  
25 154 treatment. The child recovered from the infection but could not overcome the need for  
26  
27 155 permanent tracheostomy and tracheal dilatations.  
28

## 29 156

### 30 157 Discussion

31 158 We report a case series of pediatric critically ill population who received inhaled  
32  
33 159 colistin for the treatment of tracheobronchitis (2 children) and pneumonia (1 infant).  
34  
35 160 Case 1 and 3 of tracheobronchitis were caused by *Pseudomonas aeruginosa*, while case  
36  
37 161 1 was co-infected with a multi-drug resistant *Acinetobacter baumannii* isolate. The  
38  
39 162 infection, in both these two cases, was cured with the administration of inhaled colistin  
40  
41 163 alone. The case of pneumonia was caused by *Pseudomonas aeruginosa*. This infection  
42  
43 164 was treated concurrently with intravenous antibiotics depending on susceptibility results  
44  
45 165 for the 2/3 of the total duration of inhaled colistin treatment. The outcome was cure for  
46  
47 166 this case also. Bacteriological eradication of the responsible pathogen was confirmed by  
48  
49 167 quantitative cultures of tracheobronchial secretions in all 3 cases.  
50

51 168

52 169 The rationale justifying the choice of inhaled colistin or other appropriate inhaled  
53  
54 170 antibiotics as monotherapy for the treatment of patients with tracheobronchitis is that  
55  
56 171 tracheobronchitis represents a topical inflammatory process that could be controlled  
57  
58 172 with locally administered antibiotics.<sup>12</sup> A placebo-controlled study in critically ill  
59  
60 173 patients with ventilator-associated tracheobronchitis (VAT) showed that inhaled  
174  
175 antibiotics decreased the signs of respiratory infection and the use of systemic  
antibiotics.<sup>21</sup> In our cases the only active antibiotic agent for inhalation was colistin



1  
2  
3  
4 176 based on the in vitro susceptibility pattern of the isolates. In addition, based on  
5  
6 177 preliminary evidence, adjunctive inhaled colistin to intravenous antibiotic treatment  
7  
8 178 improved the outcome of pneumonia.<sup>17,22</sup> On this ground, inhaled colistin was selected  
9  
10 179 as a therapeutic regimen for case 2.  
11  
12 180

13 181 The dosage administered to the 3 children presented in our study was 75mg of  
14  
15 182 colistimethate sodium diluted in 3 ml of normal saline, twice daily. This equals to a  
16  
17 183 daily dosage 1.875.000 IU of colistin, administered in two divided doses. According to  
18  
19 184 the national formulary, the recommended dosage of inhaled colistimethate sodium for  
20  
21 185 children older than 2 years and adults with cystic fibrosis is 1-2.000.000 IU, 2-3 times a  
22  
23 186 day. Regarding the 7.5-month-old infant in our report, the dosage of the 1.875.000 IU  
24  
25 187 per day was chosen due to her critical condition. All 3 children were closely monitored  
26  
27 188 for adverse events. No adverse event related to colistin treatment was noted in our cases.  
28  
29 189

30 190 In order to achieve the most of the benefits conferred by inhaled antibiotics in  
31  
32 191 mechanical ventilated patients several conditions should be met. The device used for  
33  
34 192 inhalation (nebulizer), the ventilator and the ventilator circuit, the inhaled agent and  
35  
36 193 patient characteristics are aspects of major significance. Nebulizers are placed at a  
37  
38 194 distance from the endotracheal tube in the inspiratory limb of the ventilator circuit and  
39  
40 195 their deliverance of small particles of the drug is achieved at the maximum with high  
41  
42 196 gas pressure and flow and low humidity as well as low gas density. In addition,  
43  
44 197 nebulizers should be operated intermittently to avoid waste of the drug during  
45  
46 198 exhalation time. Recently, a new electronic nebulizer the Pulmonary Drug Delivery  
47  
48 199 System (PDDS) utilizes information from a pressure sensor to generate the aerosol  
49  
50 200 during a specific time of the respiratory circle and that leads to delivery of the 50-70%  
51  
52 201 of the nominal dose of the drug.<sup>23</sup> Patient related factors such as severity of airway  
53  
54 202 obstruction if any, dynamic hyperinflation of the lung and synchronization with the  
55  
56 203 ventilator are important for drug delivery, as well. Specifically, evidence from published  
57  
58 204 studies suggests that colistin can be successfully nebulized with more than one of the  
59  
60 205 commercially available nebulizers.<sup>24</sup>  
206

1  
2  
3  
4 207 One fact of major importance in all three cases is that the adjunctive use of inhaled  
5  
6 208 colistin or inhaled colistin alone succeeded in the reduction and finally the total  
7  
8 209 elimination of the microbial load in respiratory secretions. When treating vulnerable  
9  
10 210 pediatric patients, issues of safety are of major concern. The administration of inhaled  
11  
12 211 colistin minimizes the risk of systemic adverse events. On the contrary, the main worry  
13  
14 212 of physicians regarding inhaled colistin is the provocation of serious  
15  
16 213 bronchoconstriction.<sup>25,26</sup> However, even though bronchoconstriction pre-existed in 2 of  
17  
18 214 our cases, it did not deteriorate with the initiation of inhaled colistin.  
19  
20 215

21 216 In conclusion, inhaled colistin was effective for the treatment of two children with  
22 217 tracheobronchitis and one infant with necrotizing pneumonia, while no adverse events  
23 218 were observed. Accumulating data on inhaled colistin use in the adult critical care  
24 219 population support its safety profile. This may provide the ground for further research  
25 220 in the pediatric critical care setting regarding inhaled colistin and its use in pediatric  
26 221 patients without cystic fibrosis.

## 222 Reference list

- 223 1. Hagerman JK, Knechtel SA, Klepser ME. Tobramycin solution for inhalation in  
224 225 cystic fibrosis patients: a review of the literature. *Expert Opin Pharmacother*  
226 227 2007;8:467-75.
- 228 2. Lenoir G, Antypkin YG, Miano A, et al. Efficacy, safety, and local pharmacokinetics  
229 230 of highly concentrated nebulized tobramycin in patients with cystic fibrosis colonized  
231 232 with *Pseudomonas aeruginosa*. *Paediatr Drugs* 2007;9 Suppl 1:11-20.
- 233 3. Ratjen F, Rietschel E, Kasel D, et al. Pharmacokinetics of inhaled colistin in patients  
234 235 with cystic fibrosis. *J Antimicrob Chemother* 2006;57:306-11.
- 236 4. Kaplan JE, Benson C, Holmes KH, Brooks JT, Pau A, Masur H. Guidelines for  
237 238 prevention and treatment of opportunistic infections in HIV-infected adults and  
239 240 adolescents: recommendations from CDC, the National Institutes of Health, and the  
241 242 HIV Medicine Association of the Infectious Diseases Society of America. *MMWR*  
243 244 *Recomm Rep* 2009;58:1-207; quiz CE1-4.
- 245 5. Checchia P. Identification and management of severe respiratory syncytial virus. *Am*  
246 247 *J Health Syst Pharm* 2008;65:S7-12.

- 1  
2  
3  
4 238 6. Eiland LS, Eiland EH. Zanamivir for the prevention of influenza in adults and  
5  
6 239 children age 5 years and older. *Ther Clin Risk Manag* 2007;3:461-5.  
7  
8 240 7. LaForce C, Man CY, Henderson FW, et al. Efficacy and safety of inhaled zanamivir  
9  
10 241 in the prevention of influenza in community-dwelling, high-risk adult and adolescent  
11  
12 242 subjects: a 28-day, multicenter, randomized, double-blind, placebo-controlled trial. *Clin*  
13  
14 243 *Ther* 2007;29:1579-90; discussion 1577-8.  
15  
16 244 8. Brochet MS, McDuff AC, Bussieres JF, et al. Comparative efficacy of two doses of  
17  
18 245 nebulized colistimethate in the eradication of *Pseudomonas aeruginosa* in children with  
19  
20 246 cystic fibrosis. *Can Respir J* 2007;14:473-9.  
21  
22 247 9. Hodson ME, Gallagher CG, Govan JR. A randomised clinical trial of nebulised  
23  
24 248 tobramycin or colistin in cystic fibrosis. *Eur Respir J* 2002;20:658-64.  
25  
26 249 10. Marchetti F, Giglio L, Candusso M, Faraguna D, Assael BM. Early antibiotic  
27  
28 250 treatment of *pseudomonas aeruginosa* colonisation in cystic fibrosis: a critical review of  
29  
30 251 the literature. *Eur J Clin Pharmacol* 2004;60:67-74.  
31  
32 252 11. Reed MD, Stern RC, O'Riordan MA, Blumer JL. The pharmacokinetics of colistin  
33  
34 253 in patients with cystic fibrosis. *J Clin Pharmacol* 2001;41:645-54.  
35  
36 254 12. Agrafiotis M, Siempos I, Falagas ME. Frequency, prevention, outcome, and  
37  
38 255 treatment of ventilator-associated tracheobronchitis: systematic review and meta-  
39  
40 256 analysis. *Respir Med* 2010;104:325-36.  
41  
42 257 13. Cook DJ, Walter SD, Cook RJ, Griffith LE, Guyatt GH, Leasa D, et al. Incidence of  
43  
44 258 and risk factors for ventilator-associated pneumonia in critically ill patients. *Ann Intern*  
45  
46 259 *Med.* 1998;129:433-40  
47  
48 260 14. Falagas ME, Kasiakou SK, Tsiodras S, Michalopoulos A. The use of intravenous  
49  
50 261 and aerosolized polymyxins for the treatment of infections in critically ill patients: a  
51  
52 262 review of the recent literature. *Clin Med Res* 2006;4:138-46.  
53  
54 263 15. Falagas ME, Siempos, II, Rafailidis PI, Korbila IP, Ioannidou E, Michalopoulos A.  
55  
56 264 Inhaled colistin as monotherapy for multidrug-resistant gram (-) nosocomial  
57  
58 265 pneumonia: a case series. *Respir Med* 2009;103:707-13.  
59  
60 266 16. Horianopoulou M, Lambropoulos S, Papafragas E, Falagas ME. Effect of  
267  
268 aerosolized colistin on multidrug-resistant *Pseudomonas aeruginosa* in bronchial  
secretions of patients without cystic fibrosis. *J Chemother* 2005;17:536-8.

- 1  
2  
3  
4 269 17. Korbila IP, Michalopoulos A, Rafailidis PI, Nikita D, Samonis G, Falagas ME.  
5  
6 270 Inhaled colistin as adjunctive to intravenous colistin for the treatment of  
7  
8 271 microbiologically documented VAP: a comparative cohort study. *Clin Microbiol Infect*  
9  
10 272 2009.  
11  
12 273 18. Michalopoulos A, Kasiakou SK, Mastora Z, Rellos K, Kapaskelis AM, Falagas ME.  
13  
14 274 Aerosolized colistin for the treatment of nosocomial pneumonia due to multidrug-  
15  
16 275 resistant Gram-negative bacteria in patients without cystic fibrosis. *Crit Care*  
17  
18 276 2005;9:R53-9.  
19  
20 277 19. Falagas ME, Sideri G, Vouloumanou EK, Papadatos JH, Kafetzis DA. Intravenous  
21  
22 278 colistimethate (colistin) use in critically ill children without cystic fibrosis. *Pediatr*  
23  
24 279 *Infect Dis J* 2009;28:123-7.  
25  
26 280 20. Falagas ME, Vouloumanou EK, Rafailidis PI. Systemic colistin use in children  
27  
28 281 without cystic fibrosis: a systematic review of the literature. *Int J Antimicrob Agents*  
29  
30 282 2009;33:503 e1- e13.  
31  
32 283 21. Palmer LB, Smaldone GC, Chen JJ, et al. Aerosolized antibiotics and ventilator-  
33  
34 284 associated tracheobronchitis in the intensive care unit. *Crit Care Med* 2008;36:2008-13.  
35  
36 285 22. Berlana D, Llop JM, Fort E, Badia MB, Jodar R. Use of colistin in the treatment of  
37  
38 286 multiple-drug-resistant gram-negative infections. *Am J Health Syst Pharm* 2005;62:39-  
39  
40 287 47.  
41  
42 288 23. Dhand R, Guntur VP. How best to deliver aerosol medications to mechanically  
43  
44 289 ventilated patients. *Clin Chest Med* 2008;29:277-96, vi.  
45  
46 290 24. Katz SL, Ho SL, Coates AL. Nebulizer choice for inhaled colistin treatment in  
47  
48 291 cystic fibrosis. *Chest* 2001;119:250-5.  
49  
50 292 25. Alothman GA, Ho B, Alsaadi MM, et al. Bronchial constriction and inhaled colistin  
51  
52 293 in cystic fibrosis. *Chest* 2005;127:522-9.  
53  
54 294 26. Cunningham S, Prasad A, Collyer L, Carr S, Lynn IB, Wallis C.  
55  
56 295 Bronchoconstriction following nebulised colistin in cystic fibrosis. *Arch Dis Child*  
57  
58 296 2001;84:432-3.  
59  
60 297

**Table. Characteristics and outcomes of critically ill children without cystic fibrosis who received inhaled colistin (colistimethate sodium) for the treatment of tracheobronchitis and pneumonia.**

	<b>Patient 1</b>	<b>Patient 2</b>	<b>Patient 3</b>
<b>Age</b>	10y	7.5mo	4y
<b>Sex</b>	M	F	F
<b>Underlying disease</b>	ADEM	None	None
<b>Reason for ICU admission</b>	Encephalomyelitis	Septic shock, necrotizing pneumonia	Respiratory burn, respiratory distress
<b>Length of stay (LOS) in the ICU</b>	≈7mo	≈1.5mo	≈3mo
<b>Length of time on the ventilator</b>	≈1.5mo (followed by tracheostomy)	≈1.5mo	11d (followed by tracheostomy)
<b>Type of infection</b>	Tracheobronchitis	Necrotizing pneumonia	Tracheobronchitis
<b>Isolated pathogen(s)</b>	<i>Acinetobacter baumannii</i> , <i>Pseudomonas aeruginosa</i>	<i>Pseudomonas aeruginosa</i>	<i>Pseudomonas aeruginosa</i>
<b>Site of isolation</b>	Bronchial culture	Bronchial culture	Bronchial culture
<b>Susceptibility pattern of the isolated pathogen(s)</b>	<i>Acinetobacter baumannii</i> Amoxicillin-clavulanic acid: S, minocycline: I, doxycycline: I, colistin: S <i>Pseudomonas aeruginosa</i> Piperacillin: S, ciprofloxacin: S, ticarcillin-clavulanate: S, aztreonam: S, piperacillin- tazobactam: S, imipenem: S, gentamicin: R, tobramycin: R, netilmicin: R, colistin: S	<i>Pseudomonas aeruginosa</i> Piperacillin: S, piperacillin- tazobactam: S, cefotaxime: R, aztreonam: S, imipenem: S, ciprofloxacin: S, gentamicin: I, tobramycin: I, netilmicin: I, colistin: S	<i>Pseudomonas aeruginosa</i> Piperacillin: S, piperacillin- tazobactam: S, ticarcillin- clavulanate: S, cefotaxime: R, aztreonam: S, ciprofloxacin: S, gentamicin: I, tobramycin: I, netilmicin: I, colistin: S
<b>Prior administration of intravenous colistin</b>	Yes*	No	Yes**
<b>Concomitant antibiotic treatment to inhaled colistin</b>	None	iv (piperacillin-tazobactam plus gentamicin for 10d, meropenem plus vancomycin for the following 11d)	None
<b>Time of institution of inhaled colistin</b>	Day 206 after ICU admission (while on tracheostomy)	Day 3 after ICU admission (while on intubation)	Day 27 after ICU admission (while on tracheostomy)
<b>Dosage of inhaled colistin</b>	75mg diluted in 3ml of normal saline twice daily	75mg diluted in 3ml of normal saline twice daily	75mg diluted in 3ml of normal saline twice daily
<b>Duration of treatment with inhaled colistin</b>	25d	32d	15d

1					
2					
3	<b>Delivery of inhaled colistin</b>	Via a nebulizer apparatus connected to the tracheostomy circuit	Via a nebulizer apparatus connected to the ventilation system	Via a nebulizer apparatus connected to the tracheostomy circuit	
4					
5	<b>Type of ventilator</b>	Siemens Servo-i Ventilator <sup>#</sup>	Siemens Servo-i Ventilator <sup>##</sup>	Siemens Servo-i Ventilator <sup>#</sup>	
6					
7	<b>Humidification</b>	On	On	On	
8					
9	<b>Quantitative change of the microbial burden of the isolated pathogen(s) (cfu/ml)/Days after institution of inhaled colistin</b>	<i>Acinetobacter baumannii</i>	<i>Pseudomonas aeruginosa</i>	<i>Pseudomonas aeruginosa</i>	
10		Day 1 >100000	1 day prior to colistin institution >100000	Day 1 >100000	
11		Day 4 95000	Day 3 100000	Day 4 80000	
12		Day 11 75000	Day 10 75000	Day 8 Rare microbes found	
13					
14		Day 17 Rare microbes found	Day 16 70000	Day 11 Natural flora	
15		Day 21 Natural flora	Day 28 5000		
16			Day 32 Natural flora		
17		<i>Pseudomonas aeruginosa</i>			
18		Day 1 >100000			
19		Day 4 75000			
20		Day 11 45000			
21		Day 17 6000			
22		Day 21 Natural flora			
23	<b>Outcome</b>	Cured from the infection	Cured from the infection	Cured from the infection	
24		Discharged from the ICU/still with tracheostomy-no colonization	Discharged from the ICU	Discharged from the ICU/still with tracheostomy-no colonization	
25					
26	<b>Adverse events</b>				
27	<b>Nephrotoxicity</b>	No	No	No	
28					
29	<b>Urea/creatinine<sup>‡</sup> (before colistin treatment–after colistin treatment)</b>	(23/0.7–25/0.6)	(47/7–15/0.3)	(30/0.5–35/0.5)	
30					
31	<b>Other toxicity</b>	No	No	No	
32					

44

45 Abbreviations: F: female, M: male, ADEM: Acute disseminated encephalomyelitis, y: year(s), mo: month(s), d: days, S: susceptibility, I: intermediate susceptibility, R: resistant, iv: intravenous.

46 ‡: mg/dl

47

48 \*: Administered for the treatment of *Acinetobacter baumannii* bacteremia.

49

50 \*\*: Administered for the treatment of *Pseudomonas aeruginosa* bacteremia.

51

52 #: Prior to colistin treatment.

53

54 ##: While on colistin treatment.

55

56

57

58

59

60